Skip to main content
Erschienen in: Drugs & Aging 6/2014

01.06.2014 | Therapy in Practice

Breakthrough Pain in Elderly Patients with Cancer: Treatment Options

verfasst von: Sophie Pautex, Nicole Vogt-Ferrier, Gilbert B. Zulian

Erschienen in: Drugs & Aging | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

The prevalence of pain is high in the elderly and increases with the occurrence of cancer. Pain treatment is challenging because of age-related factors such as co-morbidities, and over half of the patients with cancer pain experience transient exacerbation of pain that is known as breakthrough pain (BTP). As with background pain, BTP should be properly assessed before being treated. The first step to be taken is optimizing around-the-clock analgesia with expert titration of the painkiller. Rescue medication should then be provided as per the requested need, while at the same time preventing identified potential precipitating factors. In the elderly, starting treatment with a lower dose of analgesics may be justified because of age-related physiological changes such as decreased hepatic and renal function. Whenever possible, oral medication should be provided prior to a painful maneuver. In the case of unpredictable BTP, immediate rescue medication is mandatory and the subcutaneous route is preferred unless patient-controlled analgesia via continuous drug infusion is available. Recently, transmucosal preparations have appeared in the medical armamentarium but it is not yet known whether they represent a truly efficient alternative, although their rapid onset of activity is already well recognized. Adjuvant analgesics, topical analgesics, anesthetic techniques and interventional techniques are all valid methods to help in the difficult management of pain and BTP in elderly patients with cancer. However, none has reached a satisfying scientific level of evidence as to nowadays make the development of undisputed best practice guidelines possible. Further research is therefore on the agenda.
Literatur
1.
Zurück zum Zitat Davis MP, Srivastava M. Demographics, assessment and management of pain in the elderly. Drugs Aging. 2003;20:23–57.PubMedCrossRef Davis MP, Srivastava M. Demographics, assessment and management of pain in the elderly. Drugs Aging. 2003;20:23–57.PubMedCrossRef
2.
5.
Zurück zum Zitat Mercadante S, Arcuri E. Pharmacological management of cancer pain in the elderly. Drugs Aging. 2007;24:761–76.PubMedCrossRef Mercadante S, Arcuri E. Pharmacological management of cancer pain in the elderly. Drugs Aging. 2007;24:761–76.PubMedCrossRef
6.
Zurück zum Zitat AGS Panel. The management of persistent pain in older persons. J Am Geriatr Soc. 2002;50:S205–24.CrossRef AGS Panel. The management of persistent pain in older persons. J Am Geriatr Soc. 2002;50:S205–24.CrossRef
7.
Zurück zum Zitat Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129–34.PubMedCrossRef Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129–34.PubMedCrossRef
8.
Zurück zum Zitat Caraceni A, Martini C, Zecca E, Portenoy RK, Ashby MA, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain: an international survey. Palliat Med. 2004;18:77–83.CrossRef Caraceni A, Martini C, Zecca E, Portenoy RK, Ashby MA, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain: an international survey. Palliat Med. 2004;18:77–83.CrossRef
9.
Zurück zum Zitat Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care. 2009;3:1–6.PubMedCrossRef Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care. 2009;3:1–6.PubMedCrossRef
10.
Zurück zum Zitat Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331–8.PubMedCrossRef Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331–8.PubMedCrossRef
11.
Zurück zum Zitat Davies AN. The management of breakthrough cancer pain. Br J Nurs. 2011;20(803–4):806–7. Davies AN. The management of breakthrough cancer pain. Br J Nurs. 2011;20(803–4):806–7.
12.
Zurück zum Zitat Davies A, Zeppetella G, Andersen S, Damkier A, Vejlgaard T, et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain. 2011;15:756–63.PubMedCrossRef Davies A, Zeppetella G, Andersen S, Damkier A, Vejlgaard T, et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain. 2011;15:756–63.PubMedCrossRef
13.
Zurück zum Zitat American Pain Foundation. Breakthrough cancer pain: mending the break in the continuum of care. J Pain Palliat Care Pharmacother. 2011;25:252–64.PubMedCrossRef American Pain Foundation. Breakthrough cancer pain: mending the break in the continuum of care. J Pain Palliat Care Pharmacother. 2011;25:252–64.PubMedCrossRef
14.
Zurück zum Zitat Deandrea S, Corli O, Consonni D, Villani W, Greco MT, et al. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manag. 2014;47:57–76.CrossRef Deandrea S, Corli O, Consonni D, Villani W, Greco MT, et al. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manag. 2014;47:57–76.CrossRef
15.
Zurück zum Zitat Davies A, Buchanan A, Zeppetella G, Porta-Sales J, Likar R, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manag. 2013;46:619–28.CrossRef Davies A, Buchanan A, Zeppetella G, Porta-Sales J, Likar R, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manag. 2013;46:619–28.CrossRef
17.
Zurück zum Zitat Davies A. Introduction. In: Davies A, editor. Cancer-related breakthrough pain. Oxford: Oxford University Press; 2006. p. 1–11.CrossRef Davies A. Introduction. In: Davies A, editor. Cancer-related breakthrough pain. Oxford: Oxford University Press; 2006. p. 1–11.CrossRef
18.
Zurück zum Zitat Laverty D. Assessment. In: Davies A, editor. Cancer-related breakthrough pain. Oxford: Oxford University Press; 2006. p. 23–30. Laverty D. Assessment. In: Davies A, editor. Cancer-related breakthrough pain. Oxford: Oxford University Press; 2006. p. 23–30.
19.
Zurück zum Zitat Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58–68.PubMedCrossRef Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58–68.PubMedCrossRef
20.
Zurück zum Zitat Soares LG, Chan VW. The rationale for a multimodal approach in the management of breakthrough cancer pain: a review. Am J Hosp Palliat Care. 2007;24:430–9.PubMedCrossRef Soares LG, Chan VW. The rationale for a multimodal approach in the management of breakthrough cancer pain: a review. Am J Hosp Palliat Care. 2007;24:430–9.PubMedCrossRef
21.
Zurück zum Zitat Portenoy RK. Treatment of temporal variations in chronic cancer pain. Semin Oncol. 1997;24:S16-7-12.PubMed Portenoy RK. Treatment of temporal variations in chronic cancer pain. Semin Oncol. 1997;24:S16-7-12.PubMed
22.
23.
Zurück zum Zitat Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain. 2003;101:55–64.PubMedCrossRef Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain. 2003;101:55–64.PubMedCrossRef
24.
Zurück zum Zitat Hanks GW, de Conno F, Cherny N, Hanna M, Kalso E, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587–93.PubMedCentralPubMedCrossRef Hanks GW, de Conno F, Cherny N, Hanna M, Kalso E, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587–93.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Mercadante S, Villari P, Ferrera P, Casuccio A. Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manag. 2004;28:505–10.CrossRef Mercadante S, Villari P, Ferrera P, Casuccio A. Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manag. 2004;28:505–10.CrossRef
26.
Zurück zum Zitat Kalso E, Heiskanen T, Rantio M, Rosenberg PH, Vainio A. Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain. 1996;67:443–9.PubMedCrossRef Kalso E, Heiskanen T, Rantio M, Rosenberg PH, Vainio A. Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain. 1996;67:443–9.PubMedCrossRef
27.
Zurück zum Zitat Enting RH, Oldenmenger WH, van der Rijt CC, Wilms EB, Elfrink EJ, et al. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Cancer. 2002;94:3049–56.PubMedCrossRef Enting RH, Oldenmenger WH, van der Rijt CC, Wilms EB, Elfrink EJ, et al. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Cancer. 2002;94:3049–56.PubMedCrossRef
28.
Zurück zum Zitat Gannon C, Davies A. Non-opioid drugs. In: Davies A, editor. Cancer-related breakthrough pain. Oxford: Oxford University Press; 2006. p. 83–96. Gannon C, Davies A. Non-opioid drugs. In: Davies A, editor. Cancer-related breakthrough pain. Oxford: Oxford University Press; 2006. p. 83–96.
29.
30.
Zurück zum Zitat Denny DL, Guido GW. Undertreatment of pain in older adults: an application of beneficence. Nurs Ethics. 2012;19:800–9.PubMedCrossRef Denny DL, Guido GW. Undertreatment of pain in older adults: an application of beneficence. Nurs Ethics. 2012;19:800–9.PubMedCrossRef
31.
Zurück zum Zitat Ruiz-Garcia V, Lopez-Briz E. Morphine remains gold standard in breakthrough cancer pain. BMJ. 2008;337:a3104.PubMedCrossRef Ruiz-Garcia V, Lopez-Briz E. Morphine remains gold standard in breakthrough cancer pain. BMJ. 2008;337:a3104.PubMedCrossRef
32.
Zurück zum Zitat Kuo KL, Saokaew S, Stenehjem DD. The pharmacoeconomics of breakthrough cancer pain. J Pain Palliat Care Pharmacother. 2013;27:167–75.PubMedCrossRef Kuo KL, Saokaew S, Stenehjem DD. The pharmacoeconomics of breakthrough cancer pain. J Pain Palliat Care Pharmacother. 2013;27:167–75.PubMedCrossRef
33.
Zurück zum Zitat Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manag. 2013;46:573–80.CrossRef Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manag. 2013;46:573–80.CrossRef
34.
Zurück zum Zitat Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev. 2006;(1):CD004311. Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev. 2006;(1):CD004311.
35.
Zurück zum Zitat Zeppetella G. Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project. Palliat Med. 2011;25:516–24.PubMedCrossRef Zeppetella G. Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project. Palliat Med. 2011;25:516–24.PubMedCrossRef
36.
Zurück zum Zitat Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001;91:123–30.PubMedCrossRef Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001;91:123–30.PubMedCrossRef
37.
Zurück zum Zitat Kharasch ED, Hoffer C, Whittington D. Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate. Anesthesiology. 2004;101:738–43.PubMedCrossRef Kharasch ED, Hoffer C, Whittington D. Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate. Anesthesiology. 2004;101:738–43.PubMedCrossRef
38.
Zurück zum Zitat Likar R, Wittels M, Molnar M, Kager I, Ziervogel G, et al. Pharmacokinetic and pharmacodynamic properties of tramadol IR and SR in elderly patients: a prospective, age-group-controlled study. Clin Ther. 2006;28:2022–39.PubMedCrossRef Likar R, Wittels M, Molnar M, Kager I, Ziervogel G, et al. Pharmacokinetic and pharmacodynamic properties of tramadol IR and SR in elderly patients: a prospective, age-group-controlled study. Clin Ther. 2006;28:2022–39.PubMedCrossRef
39.
Zurück zum Zitat Skaer TL. Practice guidelines for transdermal opioids in malignant pain. Drugs. 2004;64:2629–38.PubMedCrossRef Skaer TL. Practice guidelines for transdermal opioids in malignant pain. Drugs. 2004;64:2629–38.PubMedCrossRef
40.
Zurück zum Zitat Davis MP, Walsh D, Lagman R, LeGrand SB. Controversies in pharmacotherapy of pain management. Lancet Oncol. 2005;6:696–704.PubMedCrossRef Davis MP, Walsh D, Lagman R, LeGrand SB. Controversies in pharmacotherapy of pain management. Lancet Oncol. 2005;6:696–704.PubMedCrossRef
41.
Zurück zum Zitat Vigano A, Bruera E, Suarez-Almazor ME. Age, pain intensity, and opioid dose in patients with advanced cancer. Cancer. 1998;83:1244–50.PubMedCrossRef Vigano A, Bruera E, Suarez-Almazor ME. Age, pain intensity, and opioid dose in patients with advanced cancer. Cancer. 1998;83:1244–50.PubMedCrossRef
42.
Zurück zum Zitat Lennernas B, Hedner T, Holmberg M, Bredenberg S, Nystrom C, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol. 2005;59:249–53.PubMedCentralPubMedCrossRef Lennernas B, Hedner T, Holmberg M, Bredenberg S, Nystrom C, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol. 2005;59:249–53.PubMedCentralPubMedCrossRef
43.
Zurück zum Zitat Mercadante S, Prestia G, Casuccio S. The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen. Curr Med Res Opin. 2013;29:1527–32.PubMedCrossRef Mercadante S, Prestia G, Casuccio S. The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen. Curr Med Res Opin. 2013;29:1527–32.PubMedCrossRef
44.
Zurück zum Zitat Gomez-Batiste X, Madrid F, Moreno F, Gracia A, Trelis J, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manag. 2002;24:45–52.CrossRef Gomez-Batiste X, Madrid F, Moreno F, Gracia A, Trelis J, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manag. 2002;24:45–52.CrossRef
45.
Zurück zum Zitat Davies AN, Vriens J, Kennett A, McTaggart M. An observational study of oncology patients’ utilization of breakthrough pain medication. J Pain Symptom Manag. 2008;35:406–11.CrossRef Davies AN, Vriens J, Kennett A, McTaggart M. An observational study of oncology patients’ utilization of breakthrough pain medication. J Pain Symptom Manag. 2008;35:406–11.CrossRef
46.
Zurück zum Zitat Sophie Lussier D, Portenoy RK. Adjuvant analgesics in pain management. In: Doyle D, Hanks G, Cherny N, Calman K, editors. Oxford textbook of palliative medicine. 3rd ed. Oxford: Oxford University Press; 2004. p. 349–78. Sophie Lussier D, Portenoy RK. Adjuvant analgesics in pain management. In: Doyle D, Hanks G, Cherny N, Calman K, editors. Oxford textbook of palliative medicine. 3rd ed. Oxford: Oxford University Press; 2004. p. 349–78.
47.
Zurück zum Zitat Semel D, Murphy TK, Zlateva G, Cheung R, Emir B. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam Pract. 2010;11:85.PubMedCentralPubMedCrossRef Semel D, Murphy TK, Zlateva G, Cheung R, Emir B. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam Pract. 2010;11:85.PubMedCentralPubMedCrossRef
48.
Zurück zum Zitat Bauer C, Lahjibi-Paulet H, Somme D, Onody P, Saint Jean O, et al. Tolerability of an equimolar mix of nitrous oxide and oxygen during painful procedures in very elderly patients. Drugs Aging. 2007;24:501–7.PubMedCrossRef Bauer C, Lahjibi-Paulet H, Somme D, Onody P, Saint Jean O, et al. Tolerability of an equimolar mix of nitrous oxide and oxygen during painful procedures in very elderly patients. Drugs Aging. 2007;24:501–7.PubMedCrossRef
49.
Zurück zum Zitat Paris A, Horvath R, Basset P, Thiery S, Couturier P, et al. Nitrous oxide-oxygen mixture during care of bedsores and painful ulcers in the elderly: a randomized, crossover, open-label pilot study. J Pain Symptom Manag. 2008;35:171–6.CrossRef Paris A, Horvath R, Basset P, Thiery S, Couturier P, et al. Nitrous oxide-oxygen mixture during care of bedsores and painful ulcers in the elderly: a randomized, crossover, open-label pilot study. J Pain Symptom Manag. 2008;35:171–6.CrossRef
50.
Zurück zum Zitat Mercadante S, Sapio M, Villari P. Suprascapular nerve block by catheter for breakthrough shoulder cancer pain. Reg Anesth. 1995;20:343–6.PubMed Mercadante S, Sapio M, Villari P. Suprascapular nerve block by catheter for breakthrough shoulder cancer pain. Reg Anesth. 1995;20:343–6.PubMed
51.
Zurück zum Zitat Zeppetella G, Ribeiro MD. Pharmacotherapy of cancer-related episodic pain. Expert Opin Pharmacother. 2003;4:493–502.PubMedCrossRef Zeppetella G, Ribeiro MD. Pharmacotherapy of cancer-related episodic pain. Expert Opin Pharmacother. 2003;4:493–502.PubMedCrossRef
52.
Zurück zum Zitat Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev. 1998;24:425–32.PubMedCrossRef Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev. 1998;24:425–32.PubMedCrossRef
53.
Zurück zum Zitat Farquhar-Smith P. Cancer-related bone pain. In: Davies A, editor. Anaesthetic/interventional techniques. Oxford: Oxford Press; 2007. p. 85–97. Farquhar-Smith P. Cancer-related bone pain. In: Davies A, editor. Anaesthetic/interventional techniques. Oxford: Oxford Press; 2007. p. 85–97.
54.
Zurück zum Zitat Burton AW, Reddy SK, Shah HN, Tremont-Lukats I, Mendel E. Percutaneous vertebroplasty—a technique to treat refractory spinal pain in the setting of advanced metastatic cancer: a case series. J Pain Symptom Manag. 2005;30:87–95.CrossRef Burton AW, Reddy SK, Shah HN, Tremont-Lukats I, Mendel E. Percutaneous vertebroplasty—a technique to treat refractory spinal pain in the setting of advanced metastatic cancer: a case series. J Pain Symptom Manag. 2005;30:87–95.CrossRef
55.
Zurück zum Zitat Swanwick M, Haworth M, Lennard RF. The prevalence of episodic pain in cancer: a survey of hospice patients on admission. Palliat Med. 2001;15:9–18.PubMedCrossRef Swanwick M, Haworth M, Lennard RF. The prevalence of episodic pain in cancer: a survey of hospice patients on admission. Palliat Med. 2001;15:9–18.PubMedCrossRef
56.
Zurück zum Zitat Fine PG, Busch MA. Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manag. 1998;16:179–83.CrossRef Fine PG, Busch MA. Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manag. 1998;16:179–83.CrossRef
57.
Zurück zum Zitat Chi GC, Young A. Selection of music for inducing relaxation and alleviating pain: literature review. Holist Nurs Pract. 2011;25:127–35.PubMedCrossRef Chi GC, Young A. Selection of music for inducing relaxation and alleviating pain: literature review. Holist Nurs Pract. 2011;25:127–35.PubMedCrossRef
58.
Zurück zum Zitat Kwekkeboom KL, Gretarsdottir E. Systematic review of relaxation interventions for pain. J Nurs Scholarsh. 2006;38:269–77.PubMedCrossRef Kwekkeboom KL, Gretarsdottir E. Systematic review of relaxation interventions for pain. J Nurs Scholarsh. 2006;38:269–77.PubMedCrossRef
59.
Zurück zum Zitat Salamon E, Esch T, Stefano GB. Pain and relaxation. Int J Mol Med. 2006;18:465–70.PubMed Salamon E, Esch T, Stefano GB. Pain and relaxation. Int J Mol Med. 2006;18:465–70.PubMed
60.
Zurück zum Zitat Ducloux D, Guisado H, Pautex S. Promoting sleep for hospitalized patients with advanced cancer with relaxation therapy: experience of a randomized study. Am J Hosp Palliat Care. 2013;30:536–40.PubMedCrossRef Ducloux D, Guisado H, Pautex S. Promoting sleep for hospitalized patients with advanced cancer with relaxation therapy: experience of a randomized study. Am J Hosp Palliat Care. 2013;30:536–40.PubMedCrossRef
Metadaten
Titel
Breakthrough Pain in Elderly Patients with Cancer: Treatment Options
verfasst von
Sophie Pautex
Nicole Vogt-Ferrier
Gilbert B. Zulian
Publikationsdatum
01.06.2014
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 6/2014
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-014-0181-5

Weitere Artikel der Ausgabe 6/2014

Drugs & Aging 6/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.